Junshi Biosciences Reports Promising Early Data for Two Key Oncology Candidates at AACR 2026 — Shanghai Junshi Biosciences Co., Ltd.

Event summary

Junshi Biosciences presented early clinical results for JS207 (PD-1/VEGF bispecific antibody) in combination therapies at AACR 2026, showing ORRs of 45.5% in advanced HCC and 71.0% in mCRC.
JS212 (EGFR/HER3 ADC) demonstrated encouraging efficacy in its first-in-human phase 1/2 study, with ORRs reaching 50.0% in HER2-negative breast cancer and 38.9% in esophageal squamous cell carcinoma.
Both JS207 and JS212 were well-tolerated in their respective studies, with no dose-limiting toxicities observed during safety run-in periods.

The big picture

Junshi Biosciences is advancing its Immuno-Oncology 2.0 strategy with promising early data for JS207 and JS212, positioning these candidates as potential next-generation therapies. The company's focus on combination strategies and broad-spectrum antitumor coverage aligns with industry trends toward more targeted and effective cancer treatments. With multiple ongoing clinical trials and regulatory approvals in place, Junshi Biosciences is poised to strengthen its position in the competitive oncology market.

What we're watching

Combination Therapy Potential: How JS207's combination with chemotherapy and JS007 will impact its development as a next-generation flagship product in immuno-oncology.
Regulatory Progress: The pace at which JS212 advances through clinical trials following FDA approval for advanced solid tumors and NMPA approval for combination studies.
Market Differentiation: Whether JS207's unique mechanism targeting both PD-1 and VEGF can position it as a superior option in immunologically cold tumors like mCRC.